Lee, Chan Joo Choi, Seungbum Cheon, Dong Huey Kim, Kyeong Yeon Cheon, Eun Jeong Ann, Soo-Jin Noh, Hye-Min Park, Sungha Kang, Seok-Min Choi, Donghoon Lee, Ji Eun Lee, Sang-Hak 2024-01-20T02:03:12Z 2024-01-20T02:03:12Z 2021-09-01 2017-02-28 1476-511X https://pubs.kist.re.kr/handle/201004/123040 Background: The influence of lipid-lowering therapy on high-density lipoprotein (HDL) is incompletely understood. We compared the effect of two lipid-lowering strategies on HDL functions and identified some HDL-related proteins. Methods: Thirty two patients were initially screened and HDLs of 21 patients were finally analyzed. Patients were randomized to receive atorvastatin 20 mg (n = 11) or atorvastatin 5 mg/ezetimibe 10 mg combination (n = 10) for 8 weeks. The cholesterol efflux capacity and other anti-inflammatory functions were assessed based on HDLs of the participants before and after treatment. Pre-specified HDL proteins of the same HDL samples were measured. Results: The post-treatment increase in cholesterol efflux capacities was similar between the groups (35.6% and 34.6% for mono-therapy and combination, respectively, p = 0.60). Changes in nitric oxide (NO) production, vascular cell adhesion molecule-1 (VCAM-1) expression, and reactive oxygen species (ROS) production were similar between the groups. The baseline cholesterol efflux capacity correlated positively with apolipoprotein (apo)A1 and C3, whereas apoA1 and apoC1 showed inverse associations with VCAM-1 expression. The changes in the cholesterol efflux capacity were positively correlated with multiple HDL proteins, especially apoA2. Conclusions: Two regimens increased the cholesterol efflux capacity of HDL comparably. Multiple HDL proteins, not limited to apoA1, showed a correlation with HDL functions. These results indicate that conventional lipid therapy may have additional effects on HDL functions with changes in HDL proteins. English BIOMED CENTRAL LTD CHOLESTEROL EFFLUX CAPACITY APOLIPOPROTEIN-C-I ANTIINFLAMMATORY PROPERTIES ENDOTHELIAL DYSFUNCTION DYSLIPIDEMIC PATIENTS TRANSPORT ACTIVATION PROTEOME METABOLISM INHIBITION Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial Article 10.1186/s12944-017-0433-6 1 LIPIDS IN HEALTH AND DISEASE, v.16 LIPIDS IN HEALTH AND DISEASE 16 scie scopus 000396786600001 2-s2.0-85014037741 Biochemistry & Molecular Biology Nutrition & Dietetics Biochemistry & Molecular Biology Nutrition & Dietetics Article CHOLESTEROL EFFLUX CAPACITY APOLIPOPROTEIN-C-I ANTIINFLAMMATORY PROPERTIES ENDOTHELIAL DYSFUNCTION DYSLIPIDEMIC PATIENTS TRANSPORT ACTIVATION PROTEOME METABOLISM INHIBITION Atorvastatin calcium Ezetimibe Cholesterol-efflux regulatory protein Inflammation